Although AMPK, an important sensor in the control of lipid homeostasis, was not fished by network pharmacology analysis, the upstream targets (leptin and adiponectin) and downstream targets (SREBP-1c, FAS, ACC-1, and CPT1a) for AMPK were all predicted for the anti-NAFLD effect of GE. Here, LEP is linked to metabolic dysfunction-associated steatotic liver disease.